Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa

Clive M. Gray, Carolyn Williamson, Helba Bredell, Adrian Puren, Xiaohua Xia, Ruben Filter, Lynn Zijenah, Huyen Cao, Lynn Morris, Efthyia Vardas, Mark Colvin, Glenda Gray, James McIntyre, Rosemary Musonda, Susan Allen, David Katzenstein, Mike Mbizo, Newton Kumwenda, Taha E Taha, Salim Abdool KarimJorge Flores, Haynes W. Sheppard

Research output: Contribution to journalArticle

Abstract

Defining viral dynamics in natural infection is prognostic of disease progression and could prove to be important for vaccine trial design as viremia may be a likely secondary end point in phase III HIV efficacy trials. There are limited data available on the early course of plasma viral load in subtype C HIV-1 infection in Africa. Plasma viral load and CD4+ T cell counts were monitored in 51 recently infected subjects for 9 months. Individuals were recruited from four southern African countries: Zambia, Malawi, Zimbabwe, and South Africa and the median estimated time from seroconversion was 8.9 months (interquartile range, 5.7-14 months). All were infected with subtype C HIV-1 and median viral loads, measured using branched DNA, ranged from 3.82-4.02 log 10 RNA copies/ml from 2-24 months after seroconversion. Viral loads significantly correlated with CD4+ cell counts (r = -0.5, p <0.0001; range, 376-364 cells/mm3) and mathematical modeling defined a median set point of 4.08 log10 (12 143 RNA copies/ml), which was attained approximately 17 months after seroconversion. Comparative measurements using three different viral load platforms (bDNA, Amplicor, and NucliSens) confirmed that viremia in subtype C HIV-1-infected individuals within the first 2 years of infection did not significantly differ from that found in early subtype B infection. In conclusion, the course of plasma viremia, as described in this study, will allow a useful baseline comparator for understanding disease progression in an African setting and may be useful in the design of HIV-1 vaccine trials in southern Africa.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume21
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Southern Africa
CD4 Lymphocyte Count
Viral Load
HIV-1
Viremia
T-Lymphocytes
Disease Progression
Infection
RNA
Zambia
Malawi
Zimbabwe
AIDS Vaccines
South Africa
HIV Infections
Vaccines
HIV
DNA
Seroconversion

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. / Gray, Clive M.; Williamson, Carolyn; Bredell, Helba; Puren, Adrian; Xia, Xiaohua; Filter, Ruben; Zijenah, Lynn; Cao, Huyen; Morris, Lynn; Vardas, Efthyia; Colvin, Mark; Gray, Glenda; McIntyre, James; Musonda, Rosemary; Allen, Susan; Katzenstein, David; Mbizo, Mike; Kumwenda, Newton; Taha, Taha E; Karim, Salim Abdool; Flores, Jorge; Sheppard, Haynes W.

In: AIDS Research and Human Retroviruses, Vol. 21, No. 4, 04.2005, p. 285-291.

Research output: Contribution to journalArticle

Gray, CM, Williamson, C, Bredell, H, Puren, A, Xia, X, Filter, R, Zijenah, L, Cao, H, Morris, L, Vardas, E, Colvin, M, Gray, G, McIntyre, J, Musonda, R, Allen, S, Katzenstein, D, Mbizo, M, Kumwenda, N, Taha, TE, Karim, SA, Flores, J & Sheppard, HW 2005, 'Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa', AIDS Research and Human Retroviruses, vol. 21, no. 4, pp. 285-291. https://doi.org/10.1089/aid.2005.21.285
Gray, Clive M. ; Williamson, Carolyn ; Bredell, Helba ; Puren, Adrian ; Xia, Xiaohua ; Filter, Ruben ; Zijenah, Lynn ; Cao, Huyen ; Morris, Lynn ; Vardas, Efthyia ; Colvin, Mark ; Gray, Glenda ; McIntyre, James ; Musonda, Rosemary ; Allen, Susan ; Katzenstein, David ; Mbizo, Mike ; Kumwenda, Newton ; Taha, Taha E ; Karim, Salim Abdool ; Flores, Jorge ; Sheppard, Haynes W. / Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. In: AIDS Research and Human Retroviruses. 2005 ; Vol. 21, No. 4. pp. 285-291.
@article{401ba3a5951849bb9d5cdd56fcffdbbb,
title = "Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa",
abstract = "Defining viral dynamics in natural infection is prognostic of disease progression and could prove to be important for vaccine trial design as viremia may be a likely secondary end point in phase III HIV efficacy trials. There are limited data available on the early course of plasma viral load in subtype C HIV-1 infection in Africa. Plasma viral load and CD4+ T cell counts were monitored in 51 recently infected subjects for 9 months. Individuals were recruited from four southern African countries: Zambia, Malawi, Zimbabwe, and South Africa and the median estimated time from seroconversion was 8.9 months (interquartile range, 5.7-14 months). All were infected with subtype C HIV-1 and median viral loads, measured using branched DNA, ranged from 3.82-4.02 log 10 RNA copies/ml from 2-24 months after seroconversion. Viral loads significantly correlated with CD4+ cell counts (r = -0.5, p <0.0001; range, 376-364 cells/mm3) and mathematical modeling defined a median set point of 4.08 log10 (12 143 RNA copies/ml), which was attained approximately 17 months after seroconversion. Comparative measurements using three different viral load platforms (bDNA, Amplicor, and NucliSens) confirmed that viremia in subtype C HIV-1-infected individuals within the first 2 years of infection did not significantly differ from that found in early subtype B infection. In conclusion, the course of plasma viremia, as described in this study, will allow a useful baseline comparator for understanding disease progression in an African setting and may be useful in the design of HIV-1 vaccine trials in southern Africa.",
author = "Gray, {Clive M.} and Carolyn Williamson and Helba Bredell and Adrian Puren and Xiaohua Xia and Ruben Filter and Lynn Zijenah and Huyen Cao and Lynn Morris and Efthyia Vardas and Mark Colvin and Glenda Gray and James McIntyre and Rosemary Musonda and Susan Allen and David Katzenstein and Mike Mbizo and Newton Kumwenda and Taha, {Taha E} and Karim, {Salim Abdool} and Jorge Flores and Sheppard, {Haynes W.}",
year = "2005",
month = "4",
doi = "10.1089/aid.2005.21.285",
language = "English (US)",
volume = "21",
pages = "285--291",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa

AU - Gray, Clive M.

AU - Williamson, Carolyn

AU - Bredell, Helba

AU - Puren, Adrian

AU - Xia, Xiaohua

AU - Filter, Ruben

AU - Zijenah, Lynn

AU - Cao, Huyen

AU - Morris, Lynn

AU - Vardas, Efthyia

AU - Colvin, Mark

AU - Gray, Glenda

AU - McIntyre, James

AU - Musonda, Rosemary

AU - Allen, Susan

AU - Katzenstein, David

AU - Mbizo, Mike

AU - Kumwenda, Newton

AU - Taha, Taha E

AU - Karim, Salim Abdool

AU - Flores, Jorge

AU - Sheppard, Haynes W.

PY - 2005/4

Y1 - 2005/4

N2 - Defining viral dynamics in natural infection is prognostic of disease progression and could prove to be important for vaccine trial design as viremia may be a likely secondary end point in phase III HIV efficacy trials. There are limited data available on the early course of plasma viral load in subtype C HIV-1 infection in Africa. Plasma viral load and CD4+ T cell counts were monitored in 51 recently infected subjects for 9 months. Individuals were recruited from four southern African countries: Zambia, Malawi, Zimbabwe, and South Africa and the median estimated time from seroconversion was 8.9 months (interquartile range, 5.7-14 months). All were infected with subtype C HIV-1 and median viral loads, measured using branched DNA, ranged from 3.82-4.02 log 10 RNA copies/ml from 2-24 months after seroconversion. Viral loads significantly correlated with CD4+ cell counts (r = -0.5, p <0.0001; range, 376-364 cells/mm3) and mathematical modeling defined a median set point of 4.08 log10 (12 143 RNA copies/ml), which was attained approximately 17 months after seroconversion. Comparative measurements using three different viral load platforms (bDNA, Amplicor, and NucliSens) confirmed that viremia in subtype C HIV-1-infected individuals within the first 2 years of infection did not significantly differ from that found in early subtype B infection. In conclusion, the course of plasma viremia, as described in this study, will allow a useful baseline comparator for understanding disease progression in an African setting and may be useful in the design of HIV-1 vaccine trials in southern Africa.

AB - Defining viral dynamics in natural infection is prognostic of disease progression and could prove to be important for vaccine trial design as viremia may be a likely secondary end point in phase III HIV efficacy trials. There are limited data available on the early course of plasma viral load in subtype C HIV-1 infection in Africa. Plasma viral load and CD4+ T cell counts were monitored in 51 recently infected subjects for 9 months. Individuals were recruited from four southern African countries: Zambia, Malawi, Zimbabwe, and South Africa and the median estimated time from seroconversion was 8.9 months (interquartile range, 5.7-14 months). All were infected with subtype C HIV-1 and median viral loads, measured using branched DNA, ranged from 3.82-4.02 log 10 RNA copies/ml from 2-24 months after seroconversion. Viral loads significantly correlated with CD4+ cell counts (r = -0.5, p <0.0001; range, 376-364 cells/mm3) and mathematical modeling defined a median set point of 4.08 log10 (12 143 RNA copies/ml), which was attained approximately 17 months after seroconversion. Comparative measurements using three different viral load platforms (bDNA, Amplicor, and NucliSens) confirmed that viremia in subtype C HIV-1-infected individuals within the first 2 years of infection did not significantly differ from that found in early subtype B infection. In conclusion, the course of plasma viremia, as described in this study, will allow a useful baseline comparator for understanding disease progression in an African setting and may be useful in the design of HIV-1 vaccine trials in southern Africa.

UR - http://www.scopus.com/inward/record.url?scp=20944442196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944442196&partnerID=8YFLogxK

U2 - 10.1089/aid.2005.21.285

DO - 10.1089/aid.2005.21.285

M3 - Article

C2 - 15943570

AN - SCOPUS:20944442196

VL - 21

SP - 285

EP - 291

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -